Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a biotechnology firm based in the United States that researches and develops small-molecule medications to treat acute diseases. For cystic fibrosis, its core medications are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and its therapies are still the gold standard of care around the world.
Key Highlights:
- Due to the international launch of KAFTRIO, total revenues climbed by 22.06% to USD 7.57 billion in FY21 (ended December 31, 2021), compared to USD 6.21 billion in FY20.
- However, VRTX's net income fell to USD 2.34 billion in FY21, compared to USD 2.71 billion in FY20.
- The company's cash conversion cycle is still long, at 106.3 days in FY21, compared to the industry norm of 77.3 days.
- Its EBITDA and net margin fell to 38.3% and 30.9% in FY21, respectively, from 47.8% and 43.7% in FY20.
- Stock is currently trading above its crucial short-term (50-day) and long-term (200-day) SMA support levels.
- Stock is leaning towards the higher band of the 52-week range of USD 176.36 to USD 254.93.
- VRTX stock price has surged 23.05% and 14.85% in the past three and six months, respectively.
Conclusion:
Considering the company's robust top line, bottom line stress, deteriorating margins, macroeconomic headwinds, and other technical indicators, we recommend a "Watch" rating on the stock at the current price of USD 230.03, up 0.0043% as of March 01, 2022, at 1:30 PM ET.
Three-Year Technical Price Chart (as of March 01, 2022, at 1:30 PM ET). Source: REFINITIV, Analysis by Kalkine Group
*The reference data in this report has been partly sourced from REFINITIV.
Tata Motors Limited
Tata Motors Limited (NYSE: TTM) is India's commercial vehicle market leader and is one of the top four-passenger vehicle manufacturers. Tata commercial and passenger vehicles are sold worldwide, including Africa, the Middle East, South Asia, South East Asia, South America, and Australia. TTM had 765.83 million American Depositary Shares (ADS) listed and outstanding (each ADS representing Five ordinary shares).
Key Highlights:
- The company's consolidated revenue from operations is INR 722.29 billion in Q3FY22 (ended December 31, 2021) vs. INR 756.54 billion in Q3FY21.
- TTM reported a consolidated loss of INR 14.51 billion in Q3FY22 compared to a profit of INR 29.41 billion in Q3FY21.
- The company's gross and EBITDA margins expanded sequentially in Q3FY22 to 41.5% and 9.9%, respectively, compared to 39.3% and 7.2% in Q2FY22.
- Stock is currently trading between its crucial short-term (50-day) and long-term (200-day) SMA support levels.
- Stock is leaning towards the higher-band of the 52-week range of USD 18.48 to USD 35.38.
- TTM stock price has surged 46.60% and 32.40% in the past six and nine months, respectively.
Conclusion:
Considering the substantial decline in topline and bottom-line metrics, incurred losses, an improvement on QoQ basis, and other technical indicators, we recommend a "Watch" rating on the stock at the current price of USD 28.85, down 4.75% as of March 01, 2022, 1:35 PM ET.
Three-Year Technical Price Chart (as of March 01, 2022, at 1:35 PM ET). Source: REFINITIV, Analysis by Kalkine Group
*The reference data in this report has been partly sourced from REFINITIV.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.